Phase I/II study of pixantrone in combination with cyclophosphamide, vincristine, and prednisone in patients with relapsed aggressive non-Hodgkin lymphoma

Leukemia and Lymphoma

Volumn 52, Issue 4, 2011, Pages 620-628

  Borchmann, Peter ^a   Herbrecht, Raoul ^b   Wilhelm, Martin ^c   Morschhauser, Franck ^d   Heß, Georg ^e   Cernohous, Paul ^f   Veals, Susan A ^f   Singer, Jack W ^f   Engert, Andreas ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b HÔPITAL DE HAUTEPIERRE   (France)

^c KLINIKUM NÜRNBERG   (Germany)

^d LILLE UNIVERSITY HOSPITAL   (France)

^e JOHANNES GUTENBERG UNIVERSITY   (Germany)

^f Cell Therapeutics Inc   (United States)

Author keywords

diffuse large B cell lymphoma; mantle cell lymphoma; non Hodgkin lymphoma; phase I study; phase II study; Pixantrone

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PIXANTRONE; PREDNISOLONE; PREDNISONE; VINCRISTINE;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ANGINA PECTORIS; ARTICLE; ASTHENIA; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CARDIAC ASTHMA; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FEBRILE NEUTROPENIA; FEMALE; HEART ATRIUM FIBRILLATION; HEART DISEASE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART PALPITATION; HEART RIGHT VENTRICLE FAILURE; HUMAN; HYPERGLYCEMIA; LEUKOPENIA; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SINUS TACHYCARDIA; TACHYCARDIA; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ISOQUINOLINES; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDNISONE; RECURRENCE; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VINCRISTINE;

EID: 79953173980     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2010.546016     Document Type: Article

References (27)

1. US Cancer Statistics Working Group. United States cancer statistics: 1999-2005 incidence and mortality web-based report. Atlanta: US Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute 2009. Available from: http://cdc.gov/uscs
2. Horner MJ, Ries LAG, Krapcho M, et al., editors. SEER Cancer Statistics Review, 1975-2006. Bethesda, MD: Na-tional Cancer Institute. [Based on November 2008 SEER data submission, posted to the SEER website 2009.] Available from: http://seer.cancer.gov/csr/1975-2006
3. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997;89: 3909-3918.
4. National Comprehensive Cancer Network. The NCCN clinical TM' practice guidelines in oncology non-Hodgkin s lymphomas (Version 1.2010). © 2009 National Comprehensive Cancer Network, Inc. Available from: http://www.nccn.org
5. Seyfarth B, Josting A, Dreyling M, Schmitz N. Relapse in common lymphoma subtypes: salvage treatment options for follicular lymphoma, diffuse large cell lymphoma and Hodgkin disease. Br J Haematol 2006;133:3-18. (Pubitemid 43328860)
6. Jantunen E, Itälä M, Juvonen E, et al. Autologous stem cell transplantation in elderly (> 60 years) patients with non-Hodgkin's lymphoma: a nation-wide analysis. Bone Marrow Transplant 2006;37:367-372. (Pubitemid 43250470)
7. Swain S, Whaley F, Ewer M. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003;97:2869-2879. (Pubitemid 36605157)
8. Rubex [package insert]. Princeton, NJ: Bristol-Meyers Squibb; 2001.
9. Hacker M, McKennon, Singer JW. Lack of iron binding by pixantrone is associated with reduced production of reactive oxygen species and myocyte cytotoxicity in vitro. Blood 2009;114(Suppl. 1): Abstract 4806.
10. Cavaletti E, Crippa L, Mainardi P, et al. Pixantrone (BBR 2778) has reduced cardiotoxic potential in mice pretreated with doxorubicin: comparative studies against doxorubicin and mitoxantrone. Invest New Drugs 2007;25:187-195. (Pubitemid 46774706)
11. Bertazzoli C, Bellini O, Magrini U, Tosana MG. Quantitative experimental evaluation of adriamycin cardiotoxicity in the mouse. CancerTreatRep 1979;63:1877-1883. (Pubitemid 10138947)
12. Evison BJ, Chiu F, Pezzoni G, et al. Formaldehyde-activated pixantrone is a monofunctional DNA alkylator that binds selectively to CpG and CpA doublets. Mol Pharmacol 2008;74:184-194. (Pubitemid 351872169)
13. Beggiolin G, Crippa L, Menta E, et al. BBR 2778, an aza-anthracenedione endowed with preclinical anticancer activity and lack of delayed cardiotoxicity. Tumorigenesis 2001;87: 407-416.
14. Pettengell R, Narayanan G, Mendoza FH, et al. Randomized phase III trial of pixantrone compared with other chemother-apeutic agents for third-line single-agent treatment ofrelapsed aggressive non-Hodgkin's lymphoma. J Clin Oncol 2009; 27(Suppl.): Abstract 8523.
15. Borchmann P, Morschhauser F, Parry A, et al. Phase-II study of the new aza-anthracenedione, BBR 2778, in patients with relapsed aggressive non-Hodgkin's lymphomas. Haematologi-ca 2003;88:888-894. (Pubitemid 37128088)
16. Fayad L, Liebmann J, Modiano M, et al. Preliminary results of a phase I/II trial of BBR-2778 (pixantrone) in combination with fludarabine, dexamethasone, and rituximab (FPD-R) in the treatment of patients with relapsed/refractory indolent non-Hodgkin's lymphoma (NHL). Blood 2004;104(Suppl. 1): Abstract 1324.
17. Lim ST, Fayad L, Tulpule A, et al. A phase I/II trial of pixantrone (BBR 2778), methylprednisolone, cisplatin, and cytosine arabinoside (PSHAP) in relapsed/refractory aggres-sive non-Hodgkin's lymphoma. Leuk Lymphoma 2007;48: 374-380. (Pubitemid 46994888)
18. Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization classification of tumors. Pathology and genetics of tumors of hematopoietic and lymphoid tissues. Lyon, France: IARC Press; 2001.
19. American Society ofClinical Oncology. Recommendations for the use ofhematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol 1994;12: 2471-2508.
20. National Cancer Institute Common Toxicity Criteria (NCI-CTC), version 2.0. [Published 30 April 1999.] Available from: http://ctep.cancer.gov/ protocolDevelopment/electronic- applications/docs/ctcv20-4-30-992.pdf
21. National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. [Published 31 March 2003, revised 10 June 2003.]. Available from: http://www.vumc. nl/afdelingen/hematologie/studiesstand/ algemeen/2458653/
22. Cheson B, Horning S, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244.
23. Dawson L, Jodrell D, Bowman A, et al. A clinical phase I and pharmacokinetic study of BBR 2778, a novel anthracenedione analogue, administered intravenously, 3 weekly. Eur J Cancer 2000;36:2353-2359.
24. Borchmann P, Schnell R, Knippertz R, et al. Phase I study of BBR 2778, a new aza-anthracenedione, in advanced or refrac-tory non-Hodgkin's lymphoma. Ann Oncol 2001;12:661-667. (Pubitemid 32519919)
25. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-242. (Pubitemid 34438862)
26. Jermann M, Jost LM, Taverna Ch, et al. Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study. Ann Oncol 2004;15:511-516. (Pubitemid 38444559)
27. Gisselbrecht C, Glass B, Mounier N, et al. R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by autologous stem cell transpla-ntation: CORAL study. J Clin Oncol 2009;27(Suppl.): Abstract 8509.